SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Xencor (XNCR)
XNCR 14.37+5.0%Nov 5 3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: scaram(o)uche9/16/2015 9:49:29 AM
1 Recommendation

Recommended By
The Ox

   of 136
 
Amgen And Xencor Announce Strategic Collaboration In Cancer Immunotherapy And InflammationCombines Amgen's Proprietary Antibodies and Xencor's XmAb® Bispecific Antibody Platform to Develop New Therapeutic Candidates
Includes Xencor's Preclinical CD38 Bispecific T Cell Engager for Multiple Myeloma
Xencor to Receive $45 Million Upfront Payment and Up to $1.7 Billion in Clinical, Regulatory and Sales Milestone Payments in Total for Six Programs

(snip)
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News